99,210 Shares in Harvard Bioscience, Inc. (NASDAQ:HBIO) Purchased by Williams & Novak LLC

Williams & Novak LLC bought a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) in the fourth quarter, Holdings Channel reports. The fund bought 99,210 shares of the medical instruments supplier’s stock, valued at approximately $209,000.

A number of other hedge funds have also added to or reduced their stakes in HBIO. Harvey Partners LLC boosted its position in shares of Harvard Bioscience by 6.2% in the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after acquiring an additional 157,500 shares during the period. Royce & Associates LP lifted its stake in Harvard Bioscience by 0.7% in the 3rd quarter. Royce & Associates LP now owns 1,451,450 shares of the medical instruments supplier’s stock worth $3,904,000 after purchasing an additional 10,000 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Harvard Bioscience by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after purchasing an additional 19,972 shares during the period. Renaissance Technologies LLC boosted its holdings in Harvard Bioscience by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after purchasing an additional 42,800 shares during the period. Finally, State Street Corp grew its position in shares of Harvard Bioscience by 1.1% during the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after purchasing an additional 7,763 shares in the last quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Trading Down 5.0 %

Shares of HBIO stock opened at $1.71 on Wednesday. Harvard Bioscience, Inc. has a 52-week low of $1.70 and a 52-week high of $4.93. The business’s fifty day moving average is $2.10 and its 200 day moving average is $2.52. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.